Brand
STELARA
STELARA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key product and says biosimilar competition was reducing sales.
Documented stakes
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission